Monopar Therapeutics (MNPR) Company Report

Monopar Therapeutics reported a net loss of $3.4 million or $0.48 per share for the third quarter ended September 30, 2025, with Research and Development (R&D) expenses at $2,589,749 and General and Administrative (G&A) expenses at $1,503,326.
As of September 30, 2025, the company's cash, cash equivalents, and investments totaled $143.7 million, which is expected to fund operations at least through December 31, 2027.
The company completed a public offering on September 23, 2025, raising approximately $91.9 million in net proceeds after a $35 million share repurchase of 550,229 shares from Tactic Pharma LLC.
Key pipeline developments include preparing to submit a New Drug Application (NDA) for ALXN1840 for Wilson disease in early 2026, and receiving FDA clearance for an IND application for MNPR-101-Lu for a Phase 1 trial in advanced solid tumors.

Nov 13, 2025, 1:00 PM

Monopar Therapeutics Presents Positive Phase 2 Data for ALXN1840 at AASLD 2025

MNPR

New Projects/Investments

Monopar Therapeutics Inc. (MNPR) presented new data and analyses from its Phase 2 ALXN1840-WD-204 copper balance study for Wilson disease at The Liver Meeting® 2025.
The study demonstrated that treatment with ALXN1840 (tiomolybdate choline) led to a rapid and sustained improvement in daily copper balance in patients, primarily through increased fecal copper excretion.
Patients treated with ALXN1840 showed a significantly lower mean daily copper balance compared to their pre-treatment baseline, indicating clinical improvement.

Nov 10, 2025, 1:00 PM

Monopar Therapeutics Presents Positive Long-Term ALXN1840 Data for Wilson Disease

MNPR

New Projects/Investments

Monopar Therapeutics announced the presentation of new long-term neurological efficacy and safety data for its investigational therapy ALXN1840 for Wilson disease at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025.
The analysis included pooled efficacy outcomes from three independent clinical trials (n=255) and safety data from four independent clinical trials (n=266), with a median treatment duration of approximately 2.6 years.
Key findings showed statistically significant sustained neurological improvement from baseline over 6 years and psychiatric improvement over multiple years.
Patients who crossed over from standard of care to ALXN1840 demonstrated additional neurological improvement, with most reversing worsening experienced on standard of care.
ALXN1840 exhibited a favorable safety profile, with less than 1% of patients experiencing a drug-related neurological serious adverse event across more than 645 patient-years.

Sep 15, 2025, 11:00 AM

Get instant answers from SEC filings, earnings calls & more

Monopar Therapeutics (MNPR)